跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD38 CAR T-cells
首页
药物
CD38 CAR T-cells
CD38 CAR T-cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD38 AND CLL1, AND USE THEREOF
WO 2025103498 A1
申请人: GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD
优先权: 2023
CN
WO
3 件公开
GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREATING SOLID TUMORS
US 2022378829 A1
申请人: CRISPR THERAPEUTICS AG
优先权: 2021
US
WO
2 件公开
GENE-EDITED NATURAL KILLER CELLS
US 20260250634 A1
申请人: CRISPR THERAPEUTICS AG
优先权: 2022
US
WO
2 件公开
NOVEL DUAL SPLIT CAR-T CELLS FOR THE TREATMENT OF CD38-POSITIVE HEMATOLOGICAL MALIGNANCIES
EP 4583905 A1
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
WO
2 件公开
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
US 11944644 B2
申请人: MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND TEL AVIV MEDICAL CT
优先权: 2018
US
2 件公开
Antibodies having specificity for CD38 and uses thereof
US 12319745 B2
申请人: INST NAT SANTE RECH MED
优先权: 2019
US
2 件公开
Construction method and application of chimeric antigen receptor T (CAR-T) cells targeting multiple antigens of multiple myeloma
CN 110577605 A
申请人: ZHEJIANG QIXIN BIOTECHNOLOGY CO LTD
优先权: 2018
CN
Bidirectional antibody recombinant exosome and preparation method thereof
CN 112941029 A
申请人: SHENZHEN SECOND PEOPLES HOSPITAL SHENZHEN INST OF TRANSLATIONAL MEDICINE
优先权: 2020
CN
Application of CD38 in preparation of CAR-T medicine
CN 113663061 A
申请人: SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD
优先权: 2021
CN
一种慢病毒载体及其应用
CN 115707780 B
申请人: 深圳市第二人民医院
优先权: 2021
CN
第 1 / 3 页
上一页
下一页
药物
反馈